TrialJournal for immunotherapy of cancer2022

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.

Jason Chesney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.